Celcuity outlines $2B peak revenue potential for gedatolisib as Phase 3 breast cancer trials progress

Stock Information for Celcuity Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Celcuity Inc.

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call 
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.